WuXi Biologics– tag –
-
Market Trends
WuXi Biologics Suzhou BioSafety Testing Center Secures Fourth EMA GMP Certification, Enabling 19 Commercial Products for European Market
WuXi Biologics China Overview WuXi Biologics' Suzhou BioSafety Testing Center has successfully renewed its European Medicines Agency (EMA) GMP certification for the fourth time. This accreditation enables the center to support quality te... -
Market Trends
Top 20 Biomanufacturing and CDMO Providers for 2026: Driving Innovation in Biopharma Production
Healthcare Ranking USA Overview The 2026 ranking of top biomanufacturing and Contract Development and Manufacturing Organization (CDMO) providers highlights industry leaders such as Lonza, Samsung Biologics, WuXi Biologics, and Thermo Fi... -
Market Trends
WuXi’s Integrated CRDMO Model: Powering Global Biopharma Innovation and Its Evolving Impact
ChinaTalk USA Overview This article from ChinaTalk analyzes WuXi Group's dominant position within the biotechnology industry, particularly its comprehensive Contract Research, Development, and Manufacturing Organization (CRDMO) model. It... -
Market Trends
WuXi Biologics Hosts Third CRDMO Day in Tokyo, Accelerating Japanese Biopharma Innovation
PR Newswire Japan Overview WuXi Biologics successfully hosted its third CRDMO Day in Tokyo, gathering key leaders and experts from Japan's biopharmaceutical sector to discuss market trends and best practices in biologics innovation. The ... -
Market Trends
Pharmaceutical Membrane Filtration Market: Size, Share, and Growth Forecast to 2034 – A Straits Research Overview
Straits Research Germany Overview This article provides an overview of a market research report published by Straits Research, detailing the pharmaceutical membrane filtration market's current status and projected growth to 2034. The rep... -
Cell Culture Technology
BIOSECURE Act Reshapes Biopharma Supply Chains, Driving API and Oligo CDMO Expansion in South Korea
CHOSUNBIZ South Korea Overview The U.S. BIOSECURE Act is catalyzing a significant shift in biopharmaceutical supply chains away from China, creating substantial opportunities for South Korean contract development and manufacturing organi...
12